2.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
Lakewood Capital Management LP Decreases Position in GoodRx Holdings, Inc. $GDRX - MarketBeat
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx approves $72,918 discretionary bonus for Chief Accounting Officer Romin Nabiey - TradingView
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds - Investing.com Nigeria
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com Australia
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Morgan Stanley Cuts Price Target on GoodRx Holdings to $3 From $4, Keeps Equalweight Rating - marketscreener.com
GDRX: GoodRx drives ~$17B in annual consumer savings and achieves profitable growth with expanding partnerships - TradingView
GoodRx Holdings GDRX Margin Improvement Reinforces Bullish Profitability Narratives - simplywall.st
GoodRx Q4 2025 Earnings: Revenue Down, Future Guidance Below EstimatesNews and Statistics - IndexBox
GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Leerink Maintains Outperform on GoodRx (GDRX) Feb 26, 2026 PT $3 - Meyka
JPMorgan Downgrades GoodRx Holdings Inc. (GDRX) to Neutral - StreetInsider
GoodRx Holdings Inc. (GDRX) PT Lowered to $1.90 at BofA Securities - StreetInsider
GoodRx Holdings Inc (GDRX) Q4 2025 Earnings Call Highlights: Pha - GuruFocus
GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions - MSN
Leerink cuts GoodRx stock price target to $3 on weak guidance - Investing.com Nigeria
Leerink cuts GoodRx stock price target to $3 on weak guidance By Investing.com - Investing.com South Africa
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):